Skip to content
Buy This GLP
← Research
Evidence

Blood Pressure Control in GLP-1 Users: What 45 Survey Responses Show

A national survey found a gap in blood pressure control. Only 45 respondents reported GLP-1 use.

Editorial profile: Neil SandersBuy This GLP Editorial Team4 min read
NHANES, 2017 to March 2020454,016Reported GLP-1 useAdults with hypertension in the sample

Trials on GLP-1 drugs and blood pressure measure changes after treatment starts. This national survey compared people at one point in time. It found differences that a randomized trial would need to put in context.

What the survey counted

The analysis used NHANES data from 2017 to March 2020. It included 4,016 U.S. adults with hypertension. Of those, 45 reported using a GLP-1 drug [1].

The estimated share below both 130 systolic and 80 diastolic was 66% among users and 24% among nonusers. After applying survey weights, the 45 users represented an estimated 994,028 adults[1]. The weights account for how people were sampled. The precision still depends on the number of respondents and the survey design [2].

Why the groups are hard to compare

The weighted share with diabetes was 99% among users and 18% among nonusers. Average BMI was also higher among users, at 37.25 versus 31.22 [1]. The groups differed substantially before considering blood pressure. The survey cannot show whether the difference came from the drug or other factors.

What randomized trials measured

A separate analysis used individual data from three semaglutide trials. Systolic blood pressure fell about 5 mmHg more with semaglutide than with placebo [3]. That measures the average change in systolic pressure. It cannot tell us how many people reached the survey cutoff.

Sources

  1. [1] Elfezzani N, Mambu TM, Nnanna JU, Iwu II, Nedassa BW, Nathan-Otu E (2026). Blood Pressure Control Among U.S. Adults With Hypertension, Stratified by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use: Evidence From the National Health and Nutrition Examination Survey, 2017-2020 Cureus. PMID 42662789
  2. [2] National Center for Health Statistics (2026). NHANES Tutorials: Reliability of Estimates Centers for Disease Control and Prevention. Source
  3. [3] Kennedy C, et al. (2024). Semaglutide and blood pressure: an individual patient data meta-analysis European Heart Journal. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence